Publication:
Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus

Simple item page
dc.contributor.authorBEREKET, ABDULLAH
dc.contributor.authorsAbali, Saygin; Turan, Serap; Atay, Zeynep; Guran, Tulay; Haliloglu, Belma; Bereket, Abdullah
dc.date.accessioned2022-03-13T12:48:27Z
dc.date.available2022-03-13T12:48:27Z
dc.date.issued2015
dc.description.abstractObjectiveWe aimed to compare hemoglobin A1c (HbA1c), total and basal insulin doses, basal insulin injection frequencies, and body mass index (BMI) in children with type 1 diabetes mellitus (T1DM) who are receiving detemir and glargine as basal insulin in a basal-bolus therapy. MethodThis retrospective study included 117 (53 females) children and adolescents with T1DM older than 4 yr of age, minimum diabetes duration of 2 yr, and receiving basal-bolus insulin regimen (at least 4 injections/d, insulin aspart or lispro as bolus insulin). Comparisons were made for those receiving insulin detemir (n = 32) or glargine (n = 85) as the basal insulin. ResultsAge, pubertal status, BMI standard deviation scores, and diabetes duration were similar in detemir and glargine groups. Glycemic control was similar in both groups (HbA1c levels 8.9 2.1% vs. 8.5 +/- 1.7% for detemir and glargine, respectively; p = 0.497). Both mean basal insulin (0.52 vs. 0.41 U/kg/d, p < 0.001) and mean total daily insulin (1.11 vs. 0.93 U/kg/d, p < 0.001) doses were higher in the detemir group. Furthermore, higher ratio of twice-daily basal insulin injection was detected in the detemir group (62.5 vs. 32.9% p = 0.004). Subgroup analysis according to pubertal status, or the number of daily basal injections showed similar results. Conclusion Insulin detemir provides similar glycemic control with glargine, but, approximately 27% higher mean basal and 19% higher mean total insulin doses with two-fold more twice-daily basal insulin injection requirement.
dc.identifier.doi10.1111/pedi.12167
dc.identifier.eissn1399-5448
dc.identifier.issn1399-543X
dc.identifier.pubmed25039448
dc.identifier.urihttps://hdl.handle.net/11424/238208
dc.identifier.wosWOS:000357833800007
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofPEDIATRIC DIABETES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectchildren
dc.subjectdetemir
dc.subjectglargine
dc.subjectHbA1c
dc.subjectT1D
dc.subjectTREAT-TO-TARGET
dc.subjectPHARMACOKINETIC PROPERTIES
dc.subjectANALOGS DETEMIR
dc.subjectSTEADY-STATE
dc.subjectDOUBLE-BLIND
dc.subjectNPH INSULIN
dc.subjectLONG
dc.subjectADOLESCENTS
dc.subjectVARIABILITY
dc.subjectPROFILE
dc.titleHigher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus
dc.typearticle
dspace.entity.typePublication
local.avesis.id418d530e-b4bc-4081-adbb-f9cb351ca4fa
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage366
oaire.citation.issue5
oaire.citation.startPage361
oaire.citation.titlePEDIATRIC DIABETES
oaire.citation.volume16
relation.isAuthorOfPublication669e9474-4e39-453f-a4bc-4ede9cb5abac
relation.isAuthorOfPublication.latestForDiscovery669e9474-4e39-453f-a4bc-4ede9cb5abac

Files

Collections

Research Outputs